AI Article Synopsis
- After administering 0.5 mg of atropine intravenously, five patients developed sustained atrioventricular (A-V) nodal reentrant tachycardia, despite having no previous signs of this condition.
- During control phases, four of these patients showed single atrial echo beats, but sustained tachycardia was not observed until atropine was given.
- Atropine improved A-V nodal conduction and adjusted the balance of conduction and refractoriness in the A-V pathways, enabling the sustained tachycardia in these cases.
Article Abstract
After intravenous administration of 0.5 mg of atropine sustained atrioventricular (A-V) nodal reentrant tachycardia could be produced in five patients who had no prior historical or electrocardiographic evidence of supraventricular tachycardia. During the control period single atrial echo beats could be demonstrated in four of the five patients, but no instance of sustained tachycardia occurred. Atropine, known to enhance A-V nodal conduction, allowed achievement of longer A-H intervals (Case 1) and provided the necessary balance of conduction and refractoriness within the A-V nodal reentrant pathways (Cases 1 to 5) to sustain A-V nodal reentry in these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9149(75)90477-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!